The licence will also increase the company’s speed-to-market as the testing and quality control process will no longer be dependent on the schedule of third-party testing laboratories.
iX Biopharma’s wholly-owned subsidiary iX Syrinx has obtained the good manufacturing practice (GMP) licence issued by the Therapeutic Goods Administration (TGA) of Australia for its testing laboratory in the state of Victoria on September 28.
With the new licence, iX Biopharma will now be able to conduct chemical and analytical laboratory testing for its commercial and developmental products in-house.
